BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31525244)

  • 1. GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve.
    Ueno H; Ito R; Abe SI; Ogino H; Maruyama M; Miyashita H; Miyamoto Y; Moritoh Y; Tsujihata Y; Takeuchi K; Nishigaki N
    PLoS One; 2019; 14(9):e0222653. PubMed ID: 31525244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity.
    Ueno H; Ito R; Abe SI; Ookawara M; Miyashita H; Ogino H; Miyamoto Y; Yoshihara T; Kobayashi A; Tsujihata Y; Takeuchi K; Watanabe M; Yamada Y; Maekawa T; Nishigaki N; Moritoh Y
    J Pharmacol Exp Ther; 2019 Aug; 370(2):172-181. PubMed ID: 31182471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GPR40 reduces food intake and body weight through GLP-1.
    Gorski JN; Pachanski MJ; Mane J; Plummer CW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Cheewatrakoolpong B; Howard AD; Colletti SL; Trujillo ME
    Am J Physiol Endocrinol Metab; 2017 Jul; 313(1):E37-E47. PubMed ID: 28292762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GPR40-Mediated G
    Rives ML; Rady B; Swanson N; Zhao S; Qi J; Arnoult E; Bakaj I; Mancini A; Breton B; Lee SP; Player MR; Pocai A
    Mol Pharmacol; 2018 Jun; 93(6):581-591. PubMed ID: 29572336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
    Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M
    PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mercaptoacetate blocks fatty acid-induced GLP-1 secretion in male rats by directly antagonizing GPR40 fatty acid receptors.
    Li AJ; Wang Q; Dinh TT; Simasko SM; Ritter S
    Am J Physiol Regul Integr Comp Physiol; 2016 Apr; 310(8):R724-32. PubMed ID: 26791830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion.
    Edfalk S; Steneberg P; Edlund H
    Diabetes; 2008 Sep; 57(9):2280-7. PubMed ID: 18519800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1.
    Mancini AD; Bertrand G; Vivot K; Carpentier É; Tremblay C; Ghislain J; Bouvier M; Poitout V
    J Biol Chem; 2015 Aug; 290(34):21131-21140. PubMed ID: 26157145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice.
    Tan CP; Feng Y; Zhou YP; Eiermann GJ; Petrov A; Zhou C; Lin S; Salituro G; Meinke P; Mosley R; Akiyama TE; Einstein M; Kumar S; Berger JP; Mills SG; Thornberry NA; Yang L; Howard AD
    Diabetes; 2008 Aug; 57(8):2211-9. PubMed ID: 18477808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
    Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
    Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models.
    Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats.
    Koyama R; Ookawara M; Watanabe M; Moritoh Y
    Mol Pharmacol; 2021 Apr; 99(4):286-293. PubMed ID: 33547250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats.
    Meidute Abaraviciene S; Muhammed SJ; Amisten S; Lundquist I; Salehi A
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):150-9. PubMed ID: 23911664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of GPR40/FFAR1 does not induce diabetes even under insulin resistance condition.
    Matsuda-Nagasumi K; Takami-Esaki R; Iwachidow K; Yasuhara Y; Tanaka H; Ogi K; Nakata M; Yano T; Hinuma S; Taketomi S; Odaka H; Kaisho Y
    Diabetes Obes Metab; 2013 Jun; 15(6):538-45. PubMed ID: 23331570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point mutation of Ffar1 abrogates fatty acid-dependent insulin secretion, but protects against HFD-induced glucose intolerance.
    Sabrautzki S; Kaiser G; Przemeck GKH; Gerst F; Lorza-Gil E; Panse M; Sartorius T; Hoene M; Marschall S; Häring HU; Hrabě de Angelis M; Ullrich S
    Mol Metab; 2017 Oct; 6(10):1304-1312. PubMed ID: 29031729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets.
    Yashiro H; Tsujihata Y; Takeuchi K; Hazama M; Johnson PR; Rorsman P
    J Pharmacol Exp Ther; 2012 Feb; 340(2):483-9. PubMed ID: 22106100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents.
    Luo J; Swaminath G; Brown SP; Zhang J; Guo Q; Chen M; Nguyen K; Tran T; Miao L; Dransfield PJ; Vimolratana M; Houze JB; Wong S; Toteva M; Shan B; Li F; Zhuang R; Lin DC
    PLoS One; 2012; 7(10):e46300. PubMed ID: 23056280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent.
    Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Cheewatrakoolpong B; Xue J; Szeto D; Forrest G; Miller C; Bunzel M; Plummer CW; Chobanian HR; Miller MW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Li X; Feng Y; Tatosian DA; Howard AD; Colletti SL; Trujillo ME
    PLoS One; 2017; 12(10):e0186033. PubMed ID: 29053717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) by free fatty acid receptor 1 (FFAR1/GPR40) protects from palmitate-induced beta cell death, but plays no role in insulin secretion.
    Panse M; Gerst F; Kaiser G; Teutsch CA; Dölker R; Wagner R; Häring HU; Ullrich S
    Cell Physiol Biochem; 2015; 35(4):1537-45. PubMed ID: 25792236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.